Showing results (111-120 of 200) with videos related to

Sort By:
Pageof 20
Cancers|January 9, 2021
The Prognostic Value of Lymph Node Involvement after Neoadjuvant Chemotherapy Is Different among Breast Cancer SubtypesLucie Laot, Enora Laas, Noemie Girard, et al.
Oncotarget|July 5, 2016
Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancersRana Hatem, Rania El Botty, Sophie Chateau-Joubert, et al.
Plos One|July 9, 2016
Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant ChemotherapyHélène Bonsang-Kitzis, Léonor Chaltier, Lisa Belin, et al.
Carcinogenesis|October 24, 2013
A siRNA screen identifies RAD21, EIF3H, CHRAC1 and TANC2 as driver genes within the 8q23, 8q24.3 and 17q23 amplicons in breast cancer with effects on cell growth, survival and transformationSardar Faisal Mahmood, Nadège Gruel, Elodie Chapeaublanc, et al.
Nature Genetics|June 2, 2019
High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancerKevin Grosselin, Adeline Durand, Justine Marsolier, et al.
International Journal of Surgery (London, England)|November 28, 2017
Sentinel lymph node biopsy validation for large tumorsGilles Houvenaeghel, Olivia Quilichini, Monique Cohen, et al.
Cancer Research|May 16, 2015
Breast Cancer Cell-Derived GM-CSF Licenses Regulatory Th2 Induction by Plasmacytoid Predendritic Cells in Aggressive Disease SubtypesCristina Ghirelli, Fabien Reyal, Marine Jeanmougin, et al.
Springerplus|August 21, 2013
Reasons of not having breast reconstruction: a historical cohort of 1937 breast cancer patients undergoing mastectomyDelphine Héquet, Kevin Zarca, Sylvie Dolbeault, et al.
Plos One|October 22, 2013
Genomic instability: a stronger prognostic marker than proliferation for early stage luminal breast carcinomasAnne Vincent-Salomon, Vanessa Benhamo, Eléonore Gravier, et al.
Cancers|July 9, 2022
No Impact of Seasonality of Diagnoses on Baseline Tumor Immune Infiltration, Response to Treatment, and Prognosis in BC Patients Treated with NACBeatriz Grandal, Ashwaq Aljehani, Elise Dumas, et al.
Pageof 20